Leo Kim has been involved in biotechnology since his industrial sabbatical at the Royal Dutch Shell Sittingbourne UK laboratory of Nobel laureate Sir John Cornforth. Leo was the R&D director of the Shell/Cetus collaboration which resulted in the Beta (ser) interferon later marketed by Biogen. As CTO of Mycogen, Leo led an international Ag biotech effort resulting in over 700 patents, $450M in sales and R&D operations on several continents resulting in the $1.2B sale to Dow Chemical. Leo was founder, CEO, and Managing director of POSCO BioVentures a $80M venture capital fund investing in companies such as Infinity Pharmaceuticals, Acorda Therapeutics, BioArrays, Geneohm, and PTC. Leo has a Ph.D. from the University of Kansas, was a research associate at MIT and was the highest ranked scientist at Shell Oil.